How Companies Decide Which Therapies to Pursue — 2023 RARE Advocacy Summit

As part of the Rare Disease Master Class: Science & Innovation track from the 2023 RARE Advocacy Summit, this panel discusses how pharmaceutical companies decide which therapies to pursue.

When the life you’ve anticipated is forever changed by rare disease, there is often an overwhelming sense of loss. This session will discuss managing many forms of grief, learning to live well in your new reality and how to find organizations and resources that can help you cope. Why do some therapies advance to clinical trials and others are discontinued? What attracts a company to pursue research on a particular project? Find out the decision factors that companies use to answer these questions.

Moderator:
Walt Kowtoniuk, PhD
Venture Partner, Third Rock Ventures

Panelists:
* Steve Rodems, PhD
VP of Research and Nonclinical Development, Travere Therapeutics

* Neil Kumar, PhD
Co-Founder and CEO, BridgeBio

* Alaa Hamed, MD, MPH, MBA
Global Head of Medical for Rare Diseases and Rare Blood Disorders, Sanofi